19 Dec 2019 |
SE Intimation |
 |
PDF 419 KB |
17 Dec 2019 |
SE Intimation |
 |
PDF 427 KB |
11 Dec 2019 |
Intimation on Appointment of ID |
 |
PDF 64 KB |
05 Dec 2019 |
Intimation of Investor/ Analyst Day |
 |
PDF 147 KB |
04 Dec 2019 |
USFDA tentative approval for Diclofenac Potassium Softgel Capsules |
 |
PDF 406 KB |
27 Nov 2019 |
SE Intimation |
 |
PDF 314 KB |
25 Nov 2019 |
Outcome of Postal Ballot – CG to Stelis |
 |
PDF 1.06 MB |
22 Nov 2019 |
Disclosure of Related Party Transactions for the half year ended September 30, 2019 |
 |
PDF 227 KB |
08 Nov 2019 |
Strides announces relaunch of Ranitidine tablets (Rx) for the US Market |
 |
PDF 402 KB |
06 Nov 2019 |
Intimation SE Merger of WoS |
 |
PDF 1.67 MB |
04 Nov 2019 |
Strides’ Ranitidine Tablets 300 mg lots tested by USFDA are within the acceptable NDMA limits |
 |
PDF 181 KB |
25 Oct 2019 |
Outcome of Board Meeting of Oct 25, 19 - Allotment of shares |
 |
PDF 421 KB |
25 Oct 2019 |
Outcome of Board Meeting of Oct 25, 19_Grant of Options |
 |
PDF 50 KB |
25 Oct 2019 |
Outcome of Board Meeting of Oct 25, 19 - Unaudited results |
 |
PDF 3.01 MB |
25 Oct 2019 |
SPSL Earnings Call Intimation |
 |
PDF 176 KB |
23 Oct 2019 |
TGA, Australia announces Ranitidine test results |
 |
PDF 421 KB |
23 Oct 2019 |
EIR from USFDA on continued GMP status for formulation facility at Alathur |
 |
PDF 146 KB |
22 Oct 2019 |
SE Intimation of Postal Ballot and Evoting |
 |
PDF 870 KB |
04 Oct 2019 |
Update on Encumbrance by Promoters |
 |
PDF 1.98 MB |
27 Sep 2019 |
Strides receives USFDA approval for Solifenacin Succinate Tablets |
 |
PDF 304 KB |
27 Sep 2019 |
Further Updates on Ranitidine Tablets for the US Markets |
 |
PDF 146 KB |
25 Sep 2019 |
Update on Ranitidine tablets |
 |
PDF 224 KB |
20 Sep 2019 |
Strides Board approves incremental investments in Stelis |
 |
PDF 316 KB |
20 Sep 2019 |
Strides Board approves incremental investments in Stelis |
 |
PDF 227 KB |
20 Sep 2019 |
Grant of Options under Strides Employee Stock Option Plan 2016 |
 |
PDF 52 KB |
11 Sep 2019 |
Strides acquires strategic stake in Fairmed Healthcare AG in Europe |
 |
PDF 320 KB |
06 Sep 2019 |
SE Intimation |
 |
PDF 302 KB |
28 Aug 2019 |
SE Intimation |
 |
PDF 206 KB |
27 Aug 2019 |
Strides acquires USFDA approved manufacturing facility in the US |
 |
PDF 349 KB |
09 Aug 2019 |
Successful completion of US FDA inspection at its Alathur facility with "Zero 483 observations" |
 |
PDF 1.4 MB |
31 Jul 2019 |
Intimation on proceeding of 28th AGM – July 30, 2019 |
 |
PDF 174 KB |
31 Jul 2019 |
Outcome of 28th AGM – July 30, 2019 |
 |
PDF 1.64 MB |
31 Jul 2019 |
Update |
 |
PDF 125 KB |
29 Jul 2019 |
Strides Outcome of the BM |
 |
PDF 3.19 MB |
29 Jul 2019 |
SE Intimation Grant of Options |
 |
PDF 55 KB |
29 Jul 2019 |
Strides Outcome of the BM - Dividend |
 |
PDF 57 KB |
29 Jul 2019 |
SPSL 2019 Merger-Intimation to SE |
 |
PDF 175 KB |
29 Jul 2019 |
Strides JVin Hong Kong |
 |
PDF 158 KB |
29 Jul 2019 |
Strides Board Meeting Outcome |
 |
PDF 3.18 MB |
29 Jul 2019 |
Strides Outcome of the BM Interim Dividend |
 |
PDF 57 KB |
29 Jul 2019 |
SPSL Earnings Call Intimation |
 |
PDF 175 KB |
23 Jul 2019 |
SE Intimation |
 |
PDF 1.7 MB |
23 Jul 2019 |
EIR from USFDA on continued GMP status for the flagship facility in Bangalore |
 |
PDF 132 KB |
20 Jul 2019 |
Strides announces successful completion of US FDA inspection at its flagship facility in Bangalore |
 |
PDF 217 KB |
17 Jul 2019 |
Clarification on the Article appeared in Economic Times on July 17, 2019 |
 |
PDF 333 KB |
10 Jul 2019 |
SE Intimation |
 |
PDF 1.72 MB |
10 Jul 2019 |
SE Intimation |
 |
PDF 1.80 MB |
10 Jul 2019 |
Update on “Strides announces final closure of Arrow transaction" |
 |
PDF 133 KB |
05 Jul 2019 |
SE Intimation - Book closure intimation and Record date |
 |
PDF 49 KB |
05 Jul 2019 |
SE Intimation - AGM Notice and Annual Report for FY 18-19 |
 |
PDF 4.13 MB |
02 Jul 2019 |
Update relating to “USFDA classifies Strides Puducherry facility as Official Action Indicated (OAI)”. |
 |
PDF 129 KB |
01 Jul 2019 |
Update on “Strides to exit its investment in Arrow for AUD 394 Million" |
 |
PDF 128 KB |
10 Jun 2019 |
SE Intimation |
 |
PDF 1.60 MB |
08 Jun 2019 |
Disclosure of Related Party Transactions for the half year ended March 31, 2019 |
 |
PDF 285 KB |
10 May 2019 |
Audited Financial Results |
 |
PDF 2.2 MB |
10 May 2019 |
Declaration of Final Dividend |
 |
PDF 117 KB |
10 May 2019 |
SPSL Earnings Call Intimation |
 |
PDF 175 KB |
07 May 2019 |
SE Intimation |
 |
PDF 1.7 MB |
06 May 2019 |
USFDA classifies Strides Puducherry facility as Official Action Initiated (OAI) |
 |
PDF 146 KB |
03 May 2019 |
Vivimed Life Sciences Private Limited (VLSPL) issues voluntary recall of 19 lots of Losartan Pottasium Tablets in USA due to detection of trace amount of N-Nitriso-N-methyl-4-aminobutyric acid (NMBA) impurity. These
lots were manufactured at VLSPL's Alathur facility prior to acquisition by Strides |
 |
PDF 535 KB |
12 Apr 2019 |
SE Intimation |
 |
PDF 183 KB |
05 Apr 2019 |
SE Intimation |
 |
PDF 841 KB |
04 Apr 2019 |
Strides pharma intimation on window closure |
 |
PDF 89 KB |
03 Apr 2019 |
SE Intimation |
 |
PDF 250 KB |
02 Apr 2019 |
Receipt of Establishment Inspection Report (EIR) from US FDA for Singapore facility |
 |
PDF 997 KB |
02 Apr 2019 |
Strides to launch Potassium Chloride Extended-Release Tablets in the US market |
 |
PDF 997 KB |
01 Apr 2019 |
Amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information |
 |
PDF 350 KB |
29 Mar 2019 |
SE Intimation |
 |
PDF 1.6 MB |
27 Mar 2019 |
SE Intimation |
 |
PDF 302 KB |
27 Mar 2019 |
SE Intimation Lachhman Dass |
 |
PDF 280 KB |
27 Mar 2019 |
USFDA approval for its greenfield oral dosage facility in Singapore |
 |
PDF 170 KB |
19 Mar 2019 |
SE Intimation |
 |
PDF 334 KB |
18 Mar 2019 |
SE Intimation |
 |
PDF 1.2 MB |
18 Mar 2019 |
SE Intimation - Lata Kapoor |
 |
PDF 1.8 MB |
15 Mar 2019 |
SE Intimation 2 |
 |
PDF 927 KB |
15 Mar 2019 |
SE Intimation |
 |
PDF 312 KB |
08 Mar 2019 |
SE Intimation |
 |
PDF 227 KB |
05 Mar 2019 |
SE Intimation |
 |
PDF 1.7 MB |
22 Feb 2019 |
SE Intimation |
 |
PDF 208 KB |
20 Feb 2019 |
SE Intimation |
 |
PDF 1.1 MB |
20 Feb 2019 |
USFDA approval for Ethosuximide Softgel Capsules |
 |
PDF 187 KB |
13 Feb 2019 |
USFDA approval for Triamcinolone Acetonide Cream |
 |
PDF 181 KB |
06 Feb 2019 |
EIR from USFDA on continued GMP status for the flagship facility in Bangalore |
 |
PDF 177 KB |
04 Feb 2019 |
SE Intimation |
 |
PDF 302 KB |
29 Jan 2019 |
Outcome of Board meeting |
 |
PDF 2.03 MB |
29 Jan 2019 |
Strides to exit its investment in Arrow |
 |
PDF 328 KB |
29 Jan 2019 |
Strides to acquire 80% stake in Pharmapar Inc. |
 |
PDF 329 KB |
29 Jan 2019 |
Strides to acquire 100% stake in Vensun Pharmaceuticals, Inc |
 |
PDF 326 KB |
29 Jan 2019 |
SPSL Earnings Call Intimation |
 |
PDF 98 KB |
25 Jan 2019 |
Strides to convert its 50:50 JV with Vivimed to 100% ownership |
 |
PDF 371 KB |
24 Jan 2019 |
SE Intimation |
 |
PDF 235 KB |
22 Jan 2019 |
SE Intimation |
 |
PDF 377 KB |
17 Jan 2019 |
SE Intimation |
 |
PDF 253 KB |
03 Jan 2019 |
SE Intimation - Rashmi Vyas |
 |
PDF 590 KB |
03 Jan 2019 |
SE Intimation - Nitha Shah |
 |
PDF 366 KB |